[12] Adverse effects [edit] Preclinical, phase I, and phase II clinical trials indicated that tirzepatide exhibits adverse effects similar to those of other established GLP-1 receptor agonists, such as dulaglutide (sold as Trulicity) and semaglutide (sold as Wegovy, Ozempic, and Rybelsus)
Structurally, it increased synaptic density (synaptophysin) in females and reduced astrogliosis (GFAP) in both sexes
One of the largest compounders canceled plans to produce an off-brand semaglutide pill under pressure from the FDA and Wegovys manufacturer, Novo Nordisk
From dosage to storage, following a clear protocol is key to a safe and effective experience
Check Dana-Farbers Health Library for additional healthy recipes for taste changes, or browse through Dana-Farbers free nutrition app for iPhone or Android.